- A Clinical Tool to Identify Incidental Meningioma for Early Outpatient Management
- Nivolumab and Ipilimumab Combination Treatment in Advanced dMMR/MSI-H Noncolorectal Cancers
- Semaglutide and Tirzepatide Prescribing in Patients With Preexisting Comorbid Cancers
- Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer
- Urinary Diversion After Cystectomy for Bladder Cancer
- Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
- Ultraprocessed Food and Early-Onset Colorectal Cancer Precursors Among Women
- Details Regarding Pneumonitis With High-Dose Aumolertinib
- Medicaid Cuts and the Future of Cancer Care
- Another Feather in the Cap for Posttransplant Cyclophosphamide GVHD Prophylaxis?
- Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced ROS1 -Positive Non−Small Cell Lung Cancer
- Details Regarding Pneumonitis With High-Dose Aumolertinib—Reply
- Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer
- Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide
- Clarifying End Point Definitions, Missingness, and Covariate Balance in the International TNT Study—Reply
